JP2025502254A - 補体因子の阻害剤及びその使用 - Google Patents

補体因子の阻害剤及びその使用 Download PDF

Info

Publication number
JP2025502254A
JP2025502254A JP2024541957A JP2024541957A JP2025502254A JP 2025502254 A JP2025502254 A JP 2025502254A JP 2024541957 A JP2024541957 A JP 2024541957A JP 2024541957 A JP2024541957 A JP 2024541957A JP 2025502254 A JP2025502254 A JP 2025502254A
Authority
JP
Japan
Prior art keywords
mmol
compound
disease
meoh
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024541957A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025502254A5 (https=
Inventor
アーティス，ディーン，アール．
レスリー，コリン，ピー．
ミレオ，ルカ，ビー．
ベアト，クラウディア
ソラナ，フェデリコ
グリエルモ，ブルーノ ディ
パドロニ，キアーラ
ファロルディ，フェデリーカ
Original Assignee
アネクソン，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アネクソン，インコーポレーテッド filed Critical アネクソン，インコーポレーテッド
Publication of JP2025502254A publication Critical patent/JP2025502254A/ja
Publication of JP2025502254A5 publication Critical patent/JP2025502254A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/027—Organoboranes and organoborohydrides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2024541957A 2022-01-14 2023-01-13 補体因子の阻害剤及びその使用 Pending JP2025502254A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263299712P 2022-01-14 2022-01-14
US63/299,712 2022-01-14
PCT/US2023/010783 WO2023137166A1 (en) 2022-01-14 2023-01-13 Inhibitors of complement factors and uses thereof

Publications (2)

Publication Number Publication Date
JP2025502254A true JP2025502254A (ja) 2025-01-24
JP2025502254A5 JP2025502254A5 (https=) 2026-01-21

Family

ID=87279676

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024541957A Pending JP2025502254A (ja) 2022-01-14 2023-01-13 補体因子の阻害剤及びその使用

Country Status (10)

Country Link
US (1) US12522619B2 (https=)
EP (1) EP4463462A4 (https=)
JP (1) JP2025502254A (https=)
KR (1) KR20240135818A (https=)
CN (1) CN118715231A (https=)
AU (1) AU2023207988A1 (https=)
CA (1) CA3248405A1 (https=)
IL (1) IL314164A (https=)
MX (1) MX2024008710A (https=)
WO (1) WO2023137166A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022020244A1 (en) 2020-07-20 2022-01-27 Annexon, Inc. Inhibitors of complement factors and uses thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965583A (en) 1997-04-24 1999-10-12 Ortho-Mcneil Pharmaceutical, Inc. Substituted imidazoles useful in the treatment of inflammatory disease
EP1971664B1 (en) 2006-01-13 2015-09-09 LG Chem, Ltd. Emitting materials and organic light emitting device using the same
KR20100031723A (ko) * 2007-07-07 2010-03-24 이데미쓰 고산 가부시키가이샤 크리센 유도체 및 이를 이용한 유기 전계 발광 소자
KR101233377B1 (ko) * 2008-12-30 2013-02-18 제일모직주식회사 신규한 유기광전소자용 화합물 및 이를 포함하는 유기광전소자
WO2013049332A1 (en) * 2011-09-29 2013-04-04 Infinity Pharmaceuticals, Inc. Inhibitors of monoacylglycerol lipase and methods of their use
WO2015003146A1 (en) 2013-07-03 2015-01-08 Georgetown University Boronic acid derivatives of resveratrol for activating deacetylase enzymes
DK3019240T3 (da) 2013-07-09 2024-06-03 Annexon Inc Anti-komplementfaktor C1Q antistoffer og anvendelser deraf
TWI532741B (zh) * 2013-09-04 2016-05-11 喜星素材股份有限公司 含吡唑之多環化合物及使用其之有機發光裝置
KR101635154B1 (ko) 2014-08-28 2016-06-30 (주)더블유에스 피리딜기가 결합된 트리아진 유도체 및 이를 포함한 유기 전계발광 소자
KR102233296B1 (ko) 2014-11-18 2021-03-29 덕산네오룩스 주식회사 유기전기 소자용 화합물, 이를 이용한 유기전기소자 및 그 전자 장치
AR103397A1 (es) 2015-01-13 2017-05-10 Syngenta Participations Ag Oxoborazoles microbicidas
US10111885B2 (en) 2015-03-13 2018-10-30 Resverlogix Corp. Compositions and therapeutic methods for the treatment of complement-associated diseases
KR101981245B1 (ko) * 2015-10-27 2019-05-22 주식회사 엘지화학 고리 화합물 및 이를 포함하는 유기 발광 소자
KR101806464B1 (ko) 2015-11-19 2017-12-07 (주)랩토 피리딜기가 결합된 피리미딘 유도체 및 이를 이용한 유기 전계 발광 소자
KR102496411B1 (ko) * 2016-01-06 2023-02-06 덕산네오룩스 주식회사 유기전기 소자용 화합물, 이를 이용한 유기전기소자 및 그 전자 장치
US10646488B2 (en) * 2016-07-13 2020-05-12 Araxes Pharma Llc Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
WO2019240471A1 (ko) 2018-06-11 2019-12-19 주식회사 엘지화학 헤테로고리 화합물 및 이를 포함하는 유기 발광 소자
WO2020032428A1 (ko) 2018-08-09 2020-02-13 덕산네오룩스 주식회사 유기전기 소자용 화합물을 포함하는 유기전기소자 및 그 전자 장치
CN109574917B (zh) 2018-12-03 2020-12-08 武汉尚赛光电科技有限公司 一种芴酮衍生物及其制备和应用
CN111087387B (zh) 2019-12-26 2022-04-29 厦门天马微电子有限公司 一种有机化合物、显示面板及显示装置
CN111423390A (zh) * 2020-03-30 2020-07-17 北京燕化集联光电技术有限公司 一种新型结构化合物及其应用
CN111662309B (zh) * 2020-07-10 2021-11-09 北京燕化集联光电技术有限公司 一种多杂环结构化合物及其应用
WO2022020244A1 (en) 2020-07-20 2022-01-27 Annexon, Inc. Inhibitors of complement factors and uses thereof
CN113045585A (zh) * 2021-03-16 2021-06-29 吉林奥来德光电材料股份有限公司 一种有机稠环化合物及其制备方法和应用
CN113831332B (zh) * 2021-10-29 2024-06-18 长春海谱润斯科技股份有限公司 一种含氮杂环衍生物及其在有机电致发光器件中的应用

Also Published As

Publication number Publication date
IL314164A (en) 2024-09-01
US12522619B2 (en) 2026-01-13
AU2023207988A1 (en) 2024-07-11
CA3248405A1 (en) 2023-07-20
EP4463462A4 (en) 2025-06-25
EP4463462A1 (en) 2024-11-20
KR20240135818A (ko) 2024-09-12
MX2024008710A (es) 2024-09-27
CN118715231A (zh) 2024-09-27
WO2023137166A1 (en) 2023-07-20
US20230265109A1 (en) 2023-08-24

Similar Documents

Publication Publication Date Title
US11377425B1 (en) Small molecule modulators of IL-17
EP2885288B1 (en) 1,4-disubstituted pyridazine analogs and methods for treating smn-deficiency-related conditions
JP7793595B2 (ja) 補体因子の阻害剤及びその使用
TW202323258A (zh) 用於治療血液病症之丙酮酸激酶活化劑
EA021359B1 (ru) N-((6-аминопиридин-3-ил)метил)гетероарилкарбоксамиды в качестве ингибиторов калликреина в плазме
JP7675020B2 (ja) Ｂａｘ阻害剤およびその使用
CA2652859A1 (en) Pyrazinones as cellular proliferation inhibitors
CN114450283A (zh) 3,6-二氨基-哒嗪-3-基衍生物、含有它们的药物组合物及其作为促凋亡剂的用途
CN110139862B (zh) 可用作romk通道抑制剂的经取代的二环杂环衍生物
JP2025502254A (ja) 補体因子の阻害剤及びその使用
WO2003090732A1 (en) Lxr modulators for the treatment of cardiovascular diseases
HK40116712A (zh) 补体因子抑制剂及其用途
EP4017844A1 (en) Compounds and use thereof for the treatment of infectious diseases and cancer
HK40096479A (zh) 补体因子的抑制剂和其用途
RU2783160C2 (ru) Гетероциклические соединения и их применение в профилактике или лечении бактериальных инфекций
HK40068269A (en) 3,6-diamino-pyridazin-3-yl derivatives, pharmaceutical compositions containing them and their uses as pro-apoptotic agents
HK40056612A (zh) 作为il-17的小分子调节剂的氨基酸苯胺类化合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240924

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20240924

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260113

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260113